兴齐眼药(300573.SZ)：SQ-129玻璃体缓释注射液获得临床试验批准通知书

Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial of SQ-129, a sustained-release injection for the treatment of diabetic macular edema and macular edema caused by retinal vein occlusion [1] Group 1 - The SQ-129 sustained-release injection is classified as a category 2 modified new chemical drug [1] - The clinical trial aims to treat adult patients with diabetic macular edema (DME) [1] - The clinical trial also targets adult patients with macular edema caused by branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) [1]